Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study

被引：0
|
作者：
Younes, A. [1 ]
Andreadis, C. [2 ]
Assouline, S. [3 ]
Rizzieri, D. [4 ]
Wedwood, A. [1 ]
McLaughlin, P. [1 ,5 ]
Laille, E.
Li, Z. [6 ]
Martell, R. E. [6 ]
Crump, M. [7 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Sir Mortimer B Davis Jewish Hosp, Montreal, PQ, Canada
[4] Duke Univ, Med Ctr, Durham, NC 27706 USA
[5] Pharmion Corp, Phamaco & PK, Boulder, CO USA
[6] MethylGene Inc, Drug Dev, Montreal, PQ, Canada
[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：162 / 162
页数：1
相关论文
共 50 条
  • [1] Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Crump, M.
    Andreadis, C.
    Assouline, S.
    Rizzieri, D.
    Wedgwood, A.
    McLaughlin, P.
    Laille, E.
    Li, Z.
    Martell, R. E.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Younes, Anas
    Wedgwood, Amanda
    McLaughlin, Peter
    Andreadis, Charalambos
    Assouline, Sarit E.
    Li, Zuomei
    Martell, Robert E.
    Dubay, Marja
    Patterson, Tracy-Ann
    Ward, Michelle R.
    Crump, Michael
    BLOOD, 2007, 110 (11) : 758A - 758A
  • [3] A phase II study of MGCD0103, a novel oral isotype-selective histone deacetylase inhibitor, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Pro, B.
    Fanale, M.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Li, Z.
    Ward, R.
    Martell, R. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 28 - 29
  • [4] Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study
    Younes, Anas
    Bociek, R. Gregory
    Kuruvilla, John
    Laneuville, Pierre
    Fung, Henry C.
    Drouin, Michel
    Patterson, Tracy
    Besterman, Jeffrey
    Martell, Robert E.
    BLOOD, 2010, 116 (21) : 735 - 735
  • [5] Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
    Younes, A.
    Kuruvilla, J.
    Pro, B.
    Wedgwood, A.
    Li, Z.
    Drouin, M.
    Patterson, T.
    Ward, R.
    Martell, R. E.
    Bociek, R. G.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [6] Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)
    Bociek, R. G.
    Kuruvilla, J.
    Pro, B.
    Wedgwood, A.
    Li, Z.
    Drouin, M.
    Patterson, T.
    Ward, R.
    Martell, R. E.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor
    Le Tourneau, Christophe
    Siu, Lillian L.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (08) : 1247 - 1254
  • [8] A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Fanale, M.
    Pro, B.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Dubay, M.
    Backstrom, J.
    Martell, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
    Garcia-Manero, Guillermo
    Assouline, Sarit
    Cortes, Jorge
    Estrov, Zeev
    Kantarjian, Hagop
    Yang, Hui
    Newsome, Willie M.
    Miller, Wilson H., Jr.
    Rousseau, Caroline
    Kalita, Ann
    Bonfils, Claire
    Dubay, Marja
    Patterson, Tracy-Ann
    Li, Zuomei
    Besterman, Jeffrey M.
    Reid, Gregory
    Laille, Eric
    Martell, Robert E.
    Minden, Mark
    BLOOD, 2008, 112 (04) : 981 - 989
  • [10] Synergistic antitumor activity of the isotype-selective histone deacetylase inhibitor MGCD0103 in combination with gemcitabine.
    Nguyen, H
    Gravel, S
    MacLeod, AR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9153S - 9154S
12345